CINECA IRIS Institutional Research Information System

GIANI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.183
EU - Europa 1.574
AS - Asia 352
AF - Africa 91
OC - Oceania 7
SA - Sud America 6
Totale 4.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.156
IT - Italia 451
DE - Germania 409
SE - Svezia 309
GB - Regno Unito 139
BG - Bulgaria 121
CN - Cina 119
SG - Singapore 98
AT - Austria 84
CI - Costa d'Avorio 53
VN - Vietnam 48
SN - Senegal 35
CA - Canada 26
IN - India 23
HK - Hong Kong 18
RU - Federazione Russa 17
JP - Giappone 15
TR - Turchia 11
IR - Iran 10
CZ - Repubblica Ceca 8
FI - Finlandia 8
AU - Australia 7
NL - Olanda 4
PH - Filippine 4
UA - Ucraina 4
FR - Francia 3
RO - Romania 3
BE - Belgio 2
CH - Svizzera 2
CL - Cile 2
GR - Grecia 2
IE - Irlanda 2
IL - Israele 2
AR - Argentina 1
BR - Brasile 1
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
ID - Indonesia 1
IQ - Iraq 1
IS - Islanda 1
KR - Corea 1
MN - Mongolia 1
MX - Messico 1
NG - Nigeria 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 4.213
Salva come PNG Salva come JPEG
Città #
Chandler 295
Fairfield 224
Woodbridge 198
Milan 191
Ashburn 165
Houston 124
Sofia 121
Seattle 116
Wilmington 101
Vienna 84
Cambridge 78
New York 75
Princeton 73
London 65
Ann Arbor 59
Boardman 57
Abidjan 53
Lawrence 50
Florence 48
Medford 41
Dakar 35
Beijing 34
Singapore 33
Frankfurt am Main 30
Serra 27
Boulder 23
Bremen 23
Redmond 23
Dong Ket 22
Munich 21
Dearborn 19
San Diego 19
Pisa 18
Rome 18
Ottawa 17
Hong Kong 16
Des Moines 15
Redwood City 15
Washington 15
Nanjing 14
Los Angeles 9
Brno 7
Izmir 7
Lancaster 7
Nanchang 7
Norwalk 7
Ogden 7
Salt Lake City 6
Scandicci 6
Tianjin 6
Chiesina Uzzanese 5
Hefei 5
Pontedera 5
Saint Louis 5
Tokyo 5
Toronto 5
Urmia 5
Ningbo 4
Sacile 4
Shanghai 4
Amsterdam 3
Bangalore 3
Civitanova Marche 3
Cleveland 3
Hatfield 3
Indiana 3
Leipzig 3
Melbourne 3
Montreal 3
Phoenix 3
San Francisco 3
Shenyang 3
Stuttgart 3
Vicopisano 3
Angri 2
Bientina 2
Changsha 2
Crick 2
Dallas 2
Dublin 2
Edinburgh 2
Epsom 2
Geneva 2
Guangzhou 2
Gurgaon 2
Hebei 2
Hyderabad 2
Jiaxing 2
Jinan 2
Kocaeli 2
Konandai 2
Makati City 2
Manila 2
New Delhi 2
Nürnberg 2
Pistoia 2
Remington 2
San Vincenzo 2
Scandiano 2
St Albans 2
Totale 2.865
Salva come PNG Salva come JPEG
Nome #
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 162
Targeted Therapy in Thyroid Cancer: State of the Art 152
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 144
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 143
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 138
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 131
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 128
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 127
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 125
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 125
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 123
Il carcinoma tiroideo: nuove prospettive terapeutiche. 121
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 118
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 115
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 114
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 111
null 105
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 104
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 103
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 95
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 92
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 88
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 88
null 86
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 83
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 82
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 73
null 70
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 69
Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy in pediatric patients 66
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 63
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 59
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 56
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 55
Correlation of the presurgical diagnosis of follicular variant of papillary thyroid cancer with the disease status after 10 years of follow-up. 55
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 54
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 52
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 51
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 51
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 50
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 49
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 43
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 42
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 42
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 39
The macrofollicular variant of papillary thyroid cancer (MF-PTC): a bicentric retrospective analysis of 65 cases. 36
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 36
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 34
Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. 32
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 31
Pre-surgical Value Of Basal Calcitonin Is Not Predictive Of Central Neck Compartment Metastases. 28
The Macrofollicular Variant of Papillary Thyroid Cancer: a retrospective analysis of 30 cases from a Single Centre. 27
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 21
Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform ¹³¹l ablation 13
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 7
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 7
Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma 6
A patient with an advanced medullary thyroid cancer and progressive, symptomatic distant metastases: When to start systemic therapy 2
Totale 4.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.497
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.497
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020687 0 0 63 68 75 86 86 48 60 67 114 20
2020/2021430 45 13 36 15 12 106 31 16 40 22 18 76
2021/2022574 13 14 11 27 111 86 6 24 34 38 51 159
2022/20231.107 137 183 88 94 102 124 14 79 189 12 80 5
2023/2024715 65 79 104 64 111 124 26 10 6 8 42 76
2024/202598 16 72 10 0 0 0 0 0 0 0 0 0
Totale 4.322